Literature DB >> 29038287

Genetic Complexity of Autosomal Dominant Polycystic Kidney and Liver Diseases.

Emilie Cornec-Le Gall1,2, Vicente E Torres1, Peter C Harris3.   

Abstract

Data indicate significant phenotypic and genotypic overlap, plus a common pathogenesis, between two groups of inherited disorders, autosomal dominant polycystic kidney diseases (ADPKD), a significant cause of ESRD, and autosomal dominant polycystic liver diseases (ADPLD), which result in significant PLD with minimal PKD. Eight genes have been associated with ADPKD (PKD1 and PKD2), ADPLD (PRKCSH, SEC63, LRP5, ALG8, and SEC61B), or both (GANAB). Although genetics is only infrequently used for diagnosing these diseases and prognosing the associated outcomes, its value is beginning to be appreciated, and the genomics revolution promises more reliable and less expensive molecular diagnostic tools for these diseases. We therefore propose categorization of patients with a phenotypic and genotypic descriptor that will clarify etiology, provide prognostic information, and better describe atypical cases. In genetically defined cases, the designation would include the disease and gene names, with allelic (truncating/nontruncating) information included for PKD1 Recent data have shown that biallelic disease including at least one weak ADPKD allele is a significant cause of symptomatic, very early onset ADPKD. Including a genic (and allelic) descriptor with the disease name will provide outcome clues, guide treatment, and aid prevalence estimates.
Copyright © 2018 by the American Society of Nephrology.

Entities:  

Keywords:  ADPKD; cystic kidney; liver cysts; polycystic kidney disease

Mesh:

Substances:

Year:  2017        PMID: 29038287      PMCID: PMC5748917          DOI: 10.1681/ASN.2017050483

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  100 in total

1.  Bilateral polycystic disease of the kidneys; a follow-up of two hundred and eighty-four patients and their families.

Authors:  O Z DALGAARD
Journal:  Acta Med Scand Suppl       Date:  1957

Review 2.  Genetics and pathogenesis of autosomal dominant polycystic kidney disease: 20 years on.

Authors:  Emilie Cornec-Le Gall; Marie-Pierre Audrézet; Yannick Le Meur; Jian-Min Chen; Claude Férec
Journal:  Hum Mutat       Date:  2014-12       Impact factor: 4.878

3.  Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing.

Authors:  Sandro Rossetti; Katharina Hopp; Robert A Sikkink; Jamie L Sundsbak; Yean Kit Lee; Vickie Kubly; Bruce W Eckloff; Christopher J Ward; Christopher G Winearls; Vicente E Torres; Peter C Harris
Journal:  J Am Soc Nephrol       Date:  2012-03-01       Impact factor: 10.121

4.  Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: a population-based study.

Authors:  Christine Patch; Judith Charlton; Paul J Roderick; Martin C Gulliford
Journal:  Am J Kidney Dis       Date:  2011-04-02       Impact factor: 8.860

5.  Polycystin-1 maturation requires polycystin-2 in a dose-dependent manner.

Authors:  Vladimir G Gainullin; Katharina Hopp; Christopher J Ward; Cynthia J Hommerding; Peter C Harris
Journal:  J Clin Invest       Date:  2015-01-09       Impact factor: 14.808

6.  Germline mutations in PRKCSH are associated with autosomal dominant polycystic liver disease.

Authors:  Joost P H Drenth; Rene H M te Morsche; Renate Smink; Juan S Bonifacino; Jan B M J Jansen
Journal:  Nat Genet       Date:  2003-02-10       Impact factor: 38.330

7.  Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity.

Authors:  Katharina Hopp; Christopher J Ward; Cynthia J Hommerding; Samih H Nasr; Han-Fang Tuan; Vladimir G Gainullin; Sandro Rossetti; Vicente E Torres; Peter C Harris
Journal:  J Clin Invest       Date:  2012-10-15       Impact factor: 14.808

8.  Mutational spectrum of the oral-facial-digital type I syndrome: a study on a large collection of patients.

Authors:  Clelia Prattichizzo; Marina Macca; Valeria Novelli; Giovanna Giorgio; Adriano Barra; Brunella Franco
Journal:  Hum Mutat       Date:  2008-10       Impact factor: 4.878

Review 9.  Polycystin-1: a master regulator of intersecting cystic pathways.

Authors:  Sorin V Fedeles; Anna-Rachel Gallagher; Stefan Somlo
Journal:  Trends Mol Med       Date:  2014-01-31       Impact factor: 11.951

10.  Unified criteria for ultrasonographic diagnosis of ADPKD.

Authors:  York Pei; James Obaji; Annie Dupuis; Andrew D Paterson; Riccardo Magistroni; Elizabeth Dicks; Patrick Parfrey; Benvon Cramer; Eliecer Coto; Roser Torra; Jose L San Millan; Robert Gibson; Martijn Breuning; Dorien Peters; David Ravine
Journal:  J Am Soc Nephrol       Date:  2008-10-22       Impact factor: 10.121

View more
  84 in total

1.  Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan.

Authors:  Matteo Bargagli; Nasser A Dhayat; Manuel Anderegg; Mariam Semmo; Uyen Huynh-Do; Bruno Vogt; Pietro Manuel Ferraro; Daniel G Fuster
Journal:  Clin J Am Soc Nephrol       Date:  2020-06-11       Impact factor: 8.237

2.  Monoallelic Mutations to DNAJB11 Cause Atypical Autosomal-Dominant Polycystic Kidney Disease.

Authors:  Emilie Cornec-Le Gall; Rory J Olson; Whitney Besse; Christina M Heyer; Vladimir G Gainullin; Jessica M Smith; Marie-Pierre Audrézet; Katharina Hopp; Binu Porath; Beili Shi; Saurabh Baheti; Sarah R Senum; Jennifer Arroyo; Charles D Madsen; Claude Férec; Dominique Joly; François Jouret; Oussamah Fikri-Benbrahim; Christophe Charasse; Jean-Marie Coulibaly; Alan S Yu; Korosh Khalili; York Pei; Stefan Somlo; Yannick Le Meur; Vicente E Torres; Peter C Harris
Journal:  Am J Hum Genet       Date:  2018-04-26       Impact factor: 11.025

3.  Fundamental insights into autosomal dominant polycystic kidney disease from human-based cell models.

Authors:  Caroline Weydert; Jean-Paul Decuypere; Humbert De Smedt; Peter Janssens; Rudi Vennekens; Djalila Mekahli
Journal:  Pediatr Nephrol       Date:  2018-09-13       Impact factor: 3.714

Review 4.  Genetic Testing in Clinical Settings.

Authors:  Nora Franceschini; Amber Frick; Jeffrey B Kopp
Journal:  Am J Kidney Dis       Date:  2018-04-11       Impact factor: 8.860

5.  Detection and characterization of mosaicism in autosomal dominant polycystic kidney disease.

Authors:  Katharina Hopp; Emilie Cornec-Le Gall; Sarah R Senum; Iris B A W Te Paske; Sonam Raj; Sravanthi Lavu; Saurabh Baheti; Marie E Edwards; Charles D Madsen; Christina M Heyer; Albert C M Ong; Kyongtae T Bae; Richard Fatica; Theodore I Steinman; Arlene B Chapman; Berenice Gitomer; Ronald D Perrone; Frederic F Rahbari-Oskoui; Vicente E Torres; Peter C Harris
Journal:  Kidney Int       Date:  2019-10-09       Impact factor: 10.612

6.  The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD.

Authors:  Sravanthi Lavu; Lisa E Vaughan; Sarah R Senum; Timothy L Kline; Arlene B Chapman; Ronald D Perrone; Michal Mrug; William E Braun; Theodore I Steinman; Frederic F Rahbari-Oskoui; Godela M Brosnahan; Kyongtae T Bae; Douglas Landsittel; Fouad T Chebib; Alan Sl Yu; Vicente E Torres; Peter C Harris
Journal:  JCI Insight       Date:  2020-08-06

7.  Prevalence Estimates of Polycystic Kidney and Liver Disease by Population Sequencing.

Authors:  Matthew B Lanktree; Amirreza Haghighi; Elsa Guiard; Ioan-Andrei Iliuta; Xuewen Song; Peter C Harris; Andrew D Paterson; York Pei
Journal:  J Am Soc Nephrol       Date:  2018-08-22       Impact factor: 10.121

Review 8.  Regulation of polycystin expression, maturation and trafficking.

Authors:  Jinghua Hu; Peter C Harris
Journal:  Cell Signal       Date:  2020-04-08       Impact factor: 4.315

9.  Severe autosomal dominant polycystic kidney disease.

Authors:  Neal S Gerstein; Craig E Rumbaugh; Julie M Riley
Journal:  BMJ Case Rep       Date:  2018-03-21

10.  The Value of Genetic Testing in Polycystic Kidney Diseases Illustrated by a Family With PKD2 and COL4A1 Mutations.

Authors:  Emilie Cornec-Le Gall; Fouad T Chebib; Charles D Madsen; Sarah R Senum; Christina M Heyer; Brendan C Lanpher; Marc C Patterson; Robert C Albright; Alan S Yu; Vicente E Torres; Peter C Harris
Journal:  Am J Kidney Dis       Date:  2018-02-01       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.